Youcare Pharmaceutical (SH:688658) Zhi Tong Cai Jing·2025-09-22 09:23Core Viewpoint - YKYY013 injection, developed by the company and its subsidiary, has received FDA approval to proceed with clinical trials for the treatment of chronic hepatitis B virus infection [1] Group 1: Company Developments - The company’s subsidiary, Beijing YKang Kechuang Pharmaceutical Technology Co., Ltd., has obtained a Study May Proceed Letter from the FDA for YKYY013 injection [1] - YKYY013 is a chemically synthesized double-stranded siRNA drug that utilizes an N-acetylgalactosamine ligand for RNA interference to silence HBV mRNA [1] Group 2: Product Details - The drug aims to inhibit the production of HBV proteins, suppress HBV replication, and create conditions for host immune reconstruction, ultimately targeting functional cure for hepatitis B [1] - The clinical application is specifically focused on treating chronic hepatitis B virus infections [1]